Antibody

Abstract

Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin β7.

1 . An anti-human integrin β 7  antibody, whose epitope is present in a region of the amino acid residue positions 20 to 109 of human integrin β 7 . 
     
     
         2 . An antibody according to  claim 1 , whose affinity for the epitope is increased in the presence of at least part of a region of the amino acid residue positions 379 to 721 of the human integrin β 7 . 
     
     
         3 . An antibody according to  claim 1  or  2 , whose affinity for the epitope is increased through activation of the human integrin β 7 . 
     
     
         4 . An antibody according to any one of  claims 1  to  3 , the antibody comprising:
 a heavy chain variable region including
 heavy-chain CDR1 having the amino acid sequence set forth in SEQ ID NO: 1, 
 heavy-chain CDR2 having the amino acid sequence set forth in SEQ ID NO: 2, and/or 
 heavy-chain CDR3 having the amino acid sequence set forth in SEQ ID NO: 3; and/or 
 
 a light chain variable region including
 light-chain CDR1 having the amino acid sequence set forth in SEQ ID NO: 6, 
 light-chain CDR2 having the amino acid sequence set forth in SEQ ID NO: 7, and/or 
 light-chain CDR3 having the amino acid sequence set forth in SEQ ID NO: 8. 
 
 
     
     
         5 . An antibody according to any one of  claims 1  to  4 , the antibody comprising:
 a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 4; and/or 
 a light chain variable region having the amino acid sequence set forth in SEQ ID NO: 9. 
 
     
     
         6 . An antibody according to any one of  claims 1  to  5 , which is a multispecific antibody. 
     
     
         7 . A polynucleotide, which has a base sequence encoding the antibody of any one of  claims 1  to  6 . 
     
     
         8 . A host cell, which harbors the polynucleotide of  claim 7 . 
     
     
         9 . A chimeric antigen receptor, comprising an antigen recognition site of the antibody of any one of  claims 1  to  6 . 
     
     
         10 . A polynucleotide, which encodes the chimeric antigen receptor of  claim 9 . 
     
     
         11 . A polynucleotide according to  claim 10 , which has the base sequence set forth in SEQ ID NO: 22. 
     
     
         12 . A cell, which harbors the polynucleotide of  claim 10  or  11 . 
     
     
         13 . A cell according to  claim 12 , which is a chimeric antigen receptor T-cell. 
     
     
         14 . A pharmaceutical composition, comprising the antibody of any one of  claims 1  to  6  or the cell of  claim 12 . 
     
     
         15 . A pharmaceutical composition, comprising the antibody of any one of  claims 1  to  6  or the chimeric antigen receptor T-cell of  claim 13 .